COPD, including chronic bronchitis and emphysema, is the third-leading cause of death in the United States, resulting in > 126,000 deaths (one in every 20 deaths) in 2005. Further, mortality due to COPD is increasing, and actuarial projections suggest that COPD will be the third-leading cause of death worldwide by the year 2020. COPD also has significant economic impact in health-care expenditure and in illness-related decreased productivity. New therapeutic approaches are, thus, desperately needed for COPD.
There is some research evidence that suggest the intravenous or inhaled stem cell treatments may have some positive health benefits in patients with COPD and improve functionality and thus improve quality of life.
The mechanisms of MSCs role in animal studies of COPD treatment may be associated with attenuating airway inflammation as well as stimulating lung tissue repair. MSC given intravenously may also potentially reduce systemic inflammation.
For more information, Visit ClinicalTrials.gov; No.: NCT00683722; URL: www.clinicaltrials.gov
At Phenicell regenerative Institute (PRI) we offer intravenous autologous bone marrow aspirate concentrate stem cells from your own body, or we offer umbilical cord blood derived mesenchymal stem cells, from a top-rated stem cell company source. Contact our office to learn more about your options.
Bratisl Lek Listy 2020;121(3):188-191. Improving effects of mesenchymal stem cells on symptoms of chronic obstructive pulmonary disease.
Xiangde Liu et al.: Review PLoS One 2016 Jun 9;11(6): Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.
Weiss, DJ, et al: A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD, Chest. 2013 Jun; 143(6): 1590–1598.